Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 123 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Reduced Glutathione Clear all
Terminated Phase 4 Interventional Results available

A Study of Glutathione in Children With Autism Spectrum Disorder

NCT05954052
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Glutathione
Drug
Lead sponsor
University of Chicago
Other
Eligibility
4 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)

NCT02288091
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Inosine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 10, 2026, 3:51 PM EDT
Withdrawn No phase listed Observational

Analysis of the Glutathione Cycle in Children With Rett Syndrome

NCT02360436
View directory record Official record
Conditions
Rett Syndrome
Interventions
Not listed
Lead sponsor
Edison Pharmaceuticals Inc
Industry
Eligibility
2 Years to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

NCT00499122
View directory record Official record
Conditions
Breast Cancer
Interventions
Cyclophosphamide, Docetaxel, Doxorubicin, NOV 002
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Miami, Florida • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Phase 2 Interventional

EPI-743 in Friedreich's Ataxia Point Mutations

NCT01962363
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
EPI-743
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 10, 2026, 3:51 PM EDT
Active, not recruiting Phase 3 Interventional

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

NCT02616484
View directory record Official record
Conditions
Pyruvate Dehydrogenase Complex Deficiency
Interventions
Dichloroacetate (DCA), Placebo, Genotype
Drug · Other · Genetic
Lead sponsor
Saol Therapeutics Inc
Industry
Eligibility
6 Months to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
10
States / cities
Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 10, 2026, 3:51 PM EDT
Completed No phase listed Observational

Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma

NCT00003793
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Sarcoma
Interventions
clonality analysis, microsatellite instability analysis, mutation analysis
Genetic
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 17 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
83
States / cities
Downey, California • Long Beach, California • Los Angeles, California + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 10, 2026, 3:51 PM EDT
Terminated Phase 2 Interventional

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

NCT04265534
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Interventions
Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Folic acid 400 -1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg
Drug · Biological · Dietary Supplement
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Phase 1 Interventional

CNS Uptake of Intranasal Glutathione

NCT02324426
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Reduced Glutathione
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 10, 2026, 3:51 PM EDT
Recruiting Phase 1 Interventional

Adia Med of Winter Park LLC Chronic Kidney Disease Research Study

NCT07572890
View directory record Official record
Conditions
Chronic Kidney Disease, Kidney Disease, Kidney Disease, Chronic, Chronic Kidney Disease (CKD), CKD
Interventions
Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione IV, Glutathione Spray, Placebo IV, Placebo Glutathione IV, Placebo Spray
Biological · Drug · Other
Lead sponsor
Adia Med of Winter Park LLC
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Milk Intervention Study for Brain Aging

NCT02957422
View directory record Official record
Conditions
Brain Aging
Interventions
1% Milk, Control
Dietary Supplement
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
60 Years to 89 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Not applicable Interventional

N-acetylcysteine in Liver Transplantation

NCT00736541
View directory record Official record
Conditions
End Stage Liver Failure
Interventions
N-acetylcysteine
Drug
Lead sponsor
Ibtesam Hilmi
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Phase 2 Interventional

Glutathione (GSH) In The Treatment of Parkinson's Disease

NCT01177319
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Glutathione
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 10, 2026, 3:51 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Combination Gerotherapeutic Interventions for Healthspan Improvement

NCT07475546
View directory record Official record
Conditions
Healthspan Improvement, Aging, Longevity
Interventions
Rapamycin, Naltrexone, Metformin, NAD+, GSH, Infinite Supplement, Placebo/control, B12, Intervention: Guided Meditation Program, Control: Podcast Listening Activity, Control: Standard Exercise Regimen, Intervention: Structured Exercise Program
Drug · Dietary Supplement · Behavioral
Lead sponsor
AgelessRx
Industry
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Glutathione Supplementation in Older Healthy Adults and Its Effect on the Number of Healthy Days Experienced During Four Months of Supplementation Compared to Placebo

NCT02438956
View directory record Official record
Conditions
Improvement in Immune Cell Function in Elderly Humans
Interventions
Setria glutathione supplement, Crystalline Cellulose
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus

NCT00333268
View directory record Official record
Conditions
Cataract
Interventions
Next Generation Ophthalmic Irrigating Solution (NGOIS), BSS Plus
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 10, 2026, 3:51 PM EDT
Active, not recruiting Phase 3 Interventional

SPI-1005 for the Treatment of Meniere's Disease (Open Label)

NCT06859788
View directory record Official record
Conditions
Meniere's Disease, Ménière's Disease
Interventions
Ebselen
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Boynton Beach, Florida • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 10, 2026, 3:51 PM EDT
Terminated Phase 3 Interventional

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

NCT04925960
View directory record Official record
Conditions
Pmm2-CDG, Phosphomannomutase 2 Deficiency, Phosphomannomutase 2 Congenital Disorder of Glycosylation, Phosphomannomutase II Congenital Disorder of Glycosylation, Phosphomannomutase II Deficiency
Interventions
Epalrestat, Placebo
Drug
Lead sponsor
Maggie's Pearl, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Not applicable Interventional Results available

Genetic Susceptibility to Ozone in Mild Asthmatic Volunteers

NCT00287365
View directory record Official record
Conditions
Mild Asthma
Interventions
ozone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Phase 3 Interventional Results available

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

NCT02311907
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
390
States / cities
Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Not applicable Interventional

Effect of Hyperbaric Therapy on Markers of Oxidative Stress in Children With Autism

NCT00263367
View directory record Official record
Conditions
Autism, Oxidative Stress
Interventions
Hyperbaric Oxygen
Other
Lead sponsor
The International Child Development Resource Center
Other
Eligibility
5 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Phase 2 Interventional

Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

NCT00700206
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
Ezatiostat Hydrochloride
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Tucson, Arizona • Alhambra, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 10, 2026, 3:51 PM EDT
Terminated Phase 2 Interventional

Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia

NCT00909584
View directory record Official record
Conditions
Severe Chronic Neutropenia
Interventions
Ezatiostat Hydrochloride
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Bethesda, Maryland • Ann Arbor, Michigan • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 10, 2026, 3:51 PM EDT
Completed Phase 1Phase 2 Interventional

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

NCT01386580
View directory record Official record
Conditions
Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, Malignant Glioma
Interventions
2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks, 2B3-101 50 mg/m2 every 3 weeks
Drug
Lead sponsor
BBB-Therapeutics B.V.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 10, 2026, 3:51 PM EDT